New on YCharts: We've added nearly 10,000 securities to our database with coverage of OTCMARKETS HIDE

Pacific Biosciences of California (PACB)

Create an Alert
2.89 +0.24  +9.06%   NASDAQ Jun 17, 8:00PM BATS Real time Currency in USD

Pacific Biosciences of California R&D Expense Quarterly:

11.98M for Dec. 31, 2012
View Full Chart

Pacific Biosciences of California R&D Expense Quarterly Chart

    Pacific Biosciences of California Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 11.98M
    Dec. 31, 2012 11.65M
    Sept. 30, 2012 12.63M
    June 30, 2012 11.27M
    March 31, 2012 12.07M
    Dec. 31, 2011 12.42M
    Sept. 30, 2011 20.00M
    June 30, 2011 19.55M
       
    March 31, 2011 24.12M
    Dec. 31, 2010 26.54M
    Sept. 30, 2010 32.87M
    June 30, 2010 27.08M
    March 31, 2010 25.32M
    Dec. 31, 2009 24.67M
    Sept. 30, 2009 21.12M

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    PACB R&D Expense Quarterly Benchmarks

    Companies
    Infinity Pharmaceuticals 20.23M
    Aegerion Pharmaceuticals 5.775M
    ARCA biopharma 0.181M

    PACB R&D Expense Quarterly Rankings

    Overall 95th percentile
    730 of 16773
    Sector 86th percentile
    190 of 1408 in Healthcare
    Industry 83rd percentile
    73 of 453 in Biotechnology

    PACB R&D Expense Quarterly Range, Past 5 Years

    Minimum 11.27M Jun 2012
    Maximum 32.87M Sep 2010
    Average 19.55M

    Access watchlists and custom data alerts.
    Start your free account.

    Registering enables you to view unlimited pages per month.

    required
    required
    required
    required
    Get Started Now

    Already registered? Sign in here.

    document.write('');